Hinge Health director reports Bessemer stock sale

A Hinge Health director reported indirect sales by Bessemer Venture Partners funds totaling over 147,000 shares at a weighted average price of $93.53.

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) director Robinson Elliott reported a sale of Class A Common Stock on September 14, 2026, carried out by affiliated Bessemer Venture Partners funds. Bessemer Venture Partners X L.P. sold 76,306 shares and Bessemer Venture Partners X Institutional L.P. sold 71,632 shares at a weighted average price of $93.53, in multiple trades between $92.71 and $93.64. Elliott has an indirect, passive economic interest through partnership interests in the Bessemer funds and disclaims beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Sale: 0 shares

Sale 1 txn

Insider Robinson Elliott

Role Director

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	0	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (2)

1. F1. On September 14, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 76,306 and 71,632 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $93.53. These shares were sold in multiple transactions at prices ranging from $92.71 to $93.64. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

Key Figures

Shares sold by BVP X L.P.: 76,306 shares Shares sold by BVP X Institutional L.P.: 71,632 shares Weighted average sale price: $93.53 per share +2 more

5 metrics

Shares sold by BVP X L.P. 76,306 shares Class A Common Stock of Hinge Health sold on September 14, 2026

Shares sold by BVP X Institutional L.P. 71,632 shares Class A Common Stock of Hinge Health sold on September 14, 2026

Weighted average sale price $93.53 per share Combined sales of Class A Common Stock by the Bessemer funds

Sale price range $92.71–$93.64 per share Multiple transactions in Hinge Health Class A Common Stock

Number of Bessemer funds transacting 2 funds Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P.

Key Terms

weighted average price, indirect, passive economic interest, pecuniary interest, beneficial ownership

4 terms

weighted average price financial

"sold 76,306 and 71,632 shares ... at a weighted average price of $93.53"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect, passive economic interest financial

"has an indirect, passive economic interest in the shares held"

pecuniary interest financial

"except to the extent of his pecuniary interest, if any, in such securities"

beneficial ownership regulatory

"disclaims beneficial ownership of the securities held by the Bessemer Funds"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HNGE director Robinson Elliott report on September 14, 2026?

He reported an indirect sale of Hinge Health Class A Common Stock by Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P., which sold 76,306 and 71,632 shares, respectively, on September 14, 2026, as disclosed in the filing's footnotes.

How many HNGE shares did the Bessemer funds sell and at what price range?

Bessemer Venture Partners X L.P. sold 76,306 shares and Bessemer Venture Partners X Institutional L.P. sold 71,632 shares of HNGE Class A Common Stock, in multiple transactions at prices ranging from $92.71 to $93.64 per share.

What was the weighted average sale price for the HNGE shares sold by the Bessemer funds?

The Bessemer funds sold their HNGE Class A Common Stock at a weighted average price of $93.53 per share, based on multiple transactions within the disclosed price range.

Does Robinson Elliott have direct ownership of the HNGE shares sold?

No. The filing states he is a partner at Bessemer Venture Partners with an indirect, passive economic interest in shares held by the Bessemer funds and disclaims beneficial ownership except to the extent of his pecuniary interest, if any.

Was the HNGE insider sale made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as using such a plan, and the footnotes do not indicate that the September 14, 2026 sales were made pursuant to a Rule 10b5-1 trading arrangement.

Can investors obtain detailed pricing for each HNGE trade in this insider sale?

Yes. The filing states the reporting person will provide, upon request, full information on the number of shares sold at each separate price within the $92.71 to $93.64 range to the issuer, any security holder, or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 05:48 PM Accepted by SEC EDGAR 09/16/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last) (First) (Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT NEW YORK 10538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/14/2026		S		0(1)	D	$0	0	I	See footnote(1)(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 14, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 76,306 and 71,632 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $93.53. These shares were sold in multiple transactions at prices ranging from $92.71 to $93.64. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)